Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 4 2Phase 3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 5Other hematologic neoplasm 3Gastrointestinal 1Dermatologic 1

Conditions

Infections 1Hepatitis C 1Carcinoma, Hepatocellular 1

Interventions

Fluorouracil 309Oxaliplatin 260Leucovorin 234Capecitabine 198Irinotecan 147Gemcitabine 128Cisplatin 126Bevacizumab 119Radiotherapy 72Paclitaxel 64Folfox protocol 56Cetuximab 56Drug Therapy 46Sorafenib 45Docetaxel 42S 1 (combination) 40Chemotherapy, Adjuvant 38Neoadjuvant Therapy 37pembrolizumab 36130-nm albumin-bound paclitaxel 28Surgical Procedures, Operative 27regorafenib 25lenvatinib 24XELOX 24Panitumumab 24Radiation 23Nivolumab 23atezolizumab 22Carboplatin 22trifluridine tipiracil drug combination 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × peginterferon alfa-2a × Gastrointestinal × Clear all
NCT01821963 2020-09-24

Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)

M.D. Anderson Cancer Center

Phase 3 Terminated
1 enrolled 3 charts
Gastrointestinal

Hepatitis C, Carcinoma, Hepatocellular, Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡